Table 1 Patient characteristics by CR Indicator at 1 year

From: Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

Factor

All patients

Less than CR within first year

CR within first year

P-value

Percent of patients w/ data

Age at registration> = 65 yr

258/3867 (7%)

194/2906 (7%)

64/961 (7%)

0.986

258/3867 (7%)

IgA

735/3086 (24%)

499/2326 (21%)

236/760 (31%)

 < 0.001

735/3086 (24%)

IgG

1868/3086 (61%)

1549/2326 (67%)

319/760 (42%)

 < 0.001

1868/3086 (61%)

Female

1380/3286 (42%)

1018/2442 (42%)

362/844 (43%)

0.542

1380/3286 (42%)

Albumin < 3.5 g/dL

1041/3443 (30%)

819/2590 (32%)

222/853 (26%)

0.002

1041/3443 (30%)

B2M > = 3.5 mg/L

1517/3681 (41%)

1126/2753 (41%)

391/928 (42%)

0.510

1517/3681 (41%)

B2M > 5.5 mg/L

708/3681 (19%)

517/2753 (19%)

191/928 (21%)

0.231

708/3681 (19%)

Creatinine > = 2 mg/dL

397/3802 (10%)

282/2852 (10%)

115/950 (12%)

0.056

397/3802 (10%)

HGB < 10 g/dL

1280/3785 (34%)

973/2842 (34%)

307/943 (33%)

0.343

1280/3785 (34%)

LDH > Upper Limit Normal

403/2244 (18%)

288/1740 (17%)

115/504 (23%)

0.002

403/2244 (18%)

Platelet Count < 150 × 10^9/L

635/3758 (17%)

454/2838 (16%)

181/920 (20%)

0.011

635/3758 (17%)

Any clonal abnormality by cytogenetics

322/1256 (26%)

209/822 (25%)

113/434 (26%)

0.814

322/1256 (26%)

BMPC > = 30%

1986/3077 (65%)

1472/2260 (65%)

514/817 (63%)

0.257

1986/3077 (65%)

ISS Stage 1

1860/2645 (70%)

1351/1949 (69%)

509/696 (73%)

0.057

1860/2645 (70%)

ISS Stage 2

1505/3302 (46%)

1121/2475 (45%)

384/827 (46%)

0.569

1505/3302 (46%)

ISS Stage 3

1242/3388 (37%)

954/2542 (38%)

288/846 (34%)

0.067

1242/3388 (37%)

  1. n/N (%): n—Number with factor, N—Number with valid data for factor
  2. ND No valid observations for factor
  3. *P-value from Fisher’s exact test, otherwise chi-squared test. P-values represent a comparison between groups, not against the overall population